Remi Barbier, Cassava Sciences CEO
October 13, 2023 07:25 AM EDT
R&D

Cas­sa­va re­sponds to ac­cu­sa­tions of 'sci­en­tif­ic mis­con­duct,' re­it­er­ates sup­port of da­ta be­hind con­tro­ver­sial Alzheimer's drug

Katherine Lewin

News Reporter

Cas­sa­va Sci­ences re­spond­ed in a state­ment Thurs­day to a re­port al­leg­ing mis­con­duct by one of its col­lab­o­ra­tors at the City Uni­ver­si­ty of New York …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times